Hamish Cameron

 

Hamish Cameron

Operating Partner

Email
hamish.cameron@svlsa.com

 

Sector
Biotechnology

 

Assistant
Paul Kilpatrick

EmailAssistants Email
paul.kilpatrick@svlsa.com

 

EmailPhone
Tel: +44 20 7421 7071

 

EmailOffice

London

Dr Hamish Cameron joined SVLS in 2008 as a Venture Partner and became an Operating Partner in 2014.  He has been Interim CEO at X2-Pharma, Delenex Therapeutics and TopiVert Pharma and Chief Commercial Officer at ESBATech. He is currently a Director at Affinium, Delenex, TopiVert and VHSquared.


Before joining SVLS, Dr Cameron was CEO of Cambridge Antibody Technology ("CAT"). Prior to that, he held a series of senior R&D positions at AstraZeneca/Zeneca including Head of the Cardiovascular Therapy Area, Senior Vice-President Medical Research and was a member of the R&D Leadership Team. Dr Cameron started his industry career with Janssen, after working in clinical practice and research in the UK. 


Hamish was trained as a physician and holds MBBS and BSc (Hons) Pharmacology degrees from the University of London. He is a member of the UK Royal College of Physicians and a Fellow and past Board member of the Faculty of Pharmaceutical Medicine.

Current Board Seats

 

Affinium Pharmaceuticals
Delenex Therapeutics (SV Life Sciences Fund IV) 
TopiVert
VHSquared